文献速递神经肌肉病

隐源性感觉性多神经病疼痛治疗的贝叶斯自适应比较效果随机试验

Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized Trial.
PubMed 文献 · JAMA Neurol · 2021-01-01

该研究为贝叶斯自适应、开放标签随机对照试验,纳入402例CSPN患者,比较去甲替林、度洛西汀、普瑞巴林和美西律在12周内减少疼痛和耐受性。结果显示去甲替林和度洛西汀的效用函数优于普瑞巴林和美西律,但无明确最优药物。

要点

  • 去甲替林和度洛西汀在疼痛缓解≥50%和退出率的复合终点上优于普瑞巴林和美西律。
  • 去甲替林效用值0.81,度洛西汀0.80,普瑞巴林0.69,美西律0.58。
  • 美西律退出率最高(58.0%),普瑞巴林次之(42.5%)。

核心结论

  • 去甲替林和度洛西汀在疼痛缓解与不良反应的综合终点上优于普瑞巴林和美西律,但无明确最优药物。

研究设计与样本

  • 贝叶斯自适应、开放标签随机对照试验,2014年12月1日至2017年10月20日在40个神经科诊所纳入402例CSPN患者。
  • 参与者随机分配至去甲替林(n=134)、度洛西汀(n=126)、普瑞巴林(n=73)或美西律(n=69)。

主要发现

  • 去甲替林效用函数0.81(95% CrI 0.69-0.93),34/134(25.4%)有效,51/134(38.1%)退出。
  • 度洛西汀效用函数0.80(95% CrI 0.68-0.92),29/126(23.0%)有效,47/126(37.3%)退出。
  • 普瑞巴林效用函数0.69(95% CrI 0.55-0.84),11/73(15.1%)有效,31/73(42.5%)退出。
  • 美西律效用函数0.58(95% CrI 0.42-0.75),14/69(20.3%)有效,40/69(58.0%)退出。
  • 各药物获得最高效用的概率:去甲替林0.52,度洛西汀0.43,普瑞巴林0.05,美西律0.00。

关键数值与推荐

  • 主要结局为效用函数,复合了12周时疼痛较基线减少≥50%的有效率和退出率。
  • 纳入标准为年龄≥30岁、数字评定量表疼痛评分≥4分(范围0-10)。

临床怎么用

  • 对于CSPN患者的神经病理性疼痛,可优先考虑去甲替林或度洛西汀,但需结合个体耐受性。
  • 美西律因退出率高,不作为首选。

局限性

  • 开放标签设计可能影响主观结局报告。
  • 样本以白人为主(85.3%),结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Cryptogenic sensory polyneuropathy (CSPN) is a common generalized slowly progressive neuropathy, second in prevalence only to diabetic neuropathy. Most patients with CSPN have significant pain. Many medications have been tried for pain reduction in CSPN, including antiepileptics, antidepressants, and sodium channel blockers. There are no comparative studies that identify the most effective medication for pain reduction in CSPN. OBJECTIVE: To determine which medication (pregabalin, duloxetine, nortriptyline, or mexiletine) is most effective for reducing neuropathic pain and best tolerated in patients with CSPN. DESIGN, SETTING, AND PARTICIPANTS: From December 1, 2014, through October 20, 2017, a bayesian adaptive, open-label randomized clinical comparative effectiveness study of pain in 402 participants with CSPN was conducted at 40 neurology care clinics. The trial included response adaptive randomization. Participants were patients with CSPN who were 30 years or older, with a pain score of 4 or greater on a numerical rating scale (range, 0-10, with higher scores indicating a higher level of pain). Participant allocation to 1 of 4 drug groups used the utility function and treatment's sample size for response adaptation randomization. At each interim analysis, a decision was made to continue enrolling (up to 400 participants) or stop the whole trial for success (80% power). Patient engagement was maintained throughout the trial, which helped guide the study and identify ways to communicate and disseminate information. Analysis was performed from December 11, 2015, to January 19, 2018. INTERVENTIONS: Participants were randomized to receive nortriptyline (n = 134), duloxetine (n = 126), pregabalin (n = 73), or mexiletine (n = 69). MAIN OUTCOMES AND MEASURES: The primary outcome was a utility function that was a composite of the efficacy (participant reported pain reduction of ≥50% from baseline to week 12) and quit (participants who discontinued medication) rates. RESULTS: Among the 402 participants (213 men [53.0%]; mean [SD] age, 60.1 [13.4] years; 343 White [85.3%]), the utility function of nortriptyline was 0.81 (95% bayesian credible interval [CrI], 0.69-0.93; 34 of 134 [25.4%] efficacious; and 51 of 134 [38.1%] quit), of duloxetine was 0.80 (95% CrI, 0.68-0.92; 29 of 126 [23.0%] efficacious; and 47 of 126 [37.3%] quit), pregabalin was 0.69 (95% CrI, 0.55-0.84; 11 of 73 [15.1%] efficacious; and 31 of 73 [42.5%] quit), and mexiletine was 0.58 (95% CrI, 0.42-0.75; 14 of 69 [20.3%] efficacious; and 40 of 69 [58.0%] quit). The probability each medication yielded the highest utility was 0.52 for nortriptyline, 0.43 for duloxetine, 0.05 for pregabalin, and 0.00 for mexiletine. CONCLUSIONS AND RELEVANCE: This study found that, although there was no clearly superior medication, nortriptyline and duloxetine outperformed pregabalin and mexiletine when pain reduction and undesirable adverse effects are combined to a single end point. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02260388.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Barohn RJ, Gajewski B, Pasnoor M, et al. Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized Trial. JAMA Neurol. 2021. PMID: 32809014. doi:10.1001/jamaneurol.2020.2590

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。